This page is updated frequently with new Recombinant-related patent applications.
|Novel biological detection dioxins in serum, and a diagnostic use therefor in metabolic syndrome and related conditions|
The present invention relates to a novel biological detection method for dioxins in serum and a diagnostic use thereof in metabolic syndrome and related conditions. More particularly, according to the present invention, a significant correlation between dioxin content in serum and physical variables has been confirmed by measuring luciferase activity through the use of serum as a whole and cells transformed with a recombinant vector comprising a gene construct in which a dioxin responsive element, a promoter and a reporter gene are operably linked.
University-industry Cooperation Group Of Kyung Hee
|E1 enzyme mutants and uses thereof|
The invention provides isolated nucleic acids molecules, designated uba3, uae, or uba6, or other e1 enzyme variant nucleic acid molecules, which encode novel e1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing uba3, uae, or uba6, or other e1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a uba3, uae, or uba6, or other e1 enzyme variant gene has been introduced or disrupted.
Millennium Pharmaceuticals, Inc.
|Surface display of whole antibodies in eukaryotes|
Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest..
Merck Sharp & Dohme Corp.
|Novel methods, polypeptides and uses thereof|
The present invention provides methods for the production of recombinant polypeptides having serine protease activity, polypeptides obtainable by such methods and use of said polypeptides in medicine, cosmetics and industry. In particular, the invention provides recombinantly expressed mutants of trypsin i from atlantic cod, which mutants exhibit improved stability and/or catalytic properties relative to the wildtype trypsin purified from cod..
|Oncolytic heterologous recombinant newcastle disease virus, preparation method and application thereof|
Provided are an oncolytic heterologous recombinant newcastle disease virus (ndv), preparation method and application thereof. The heterologous recombinant ndv can express alpha (1,3) galactosyltransferase (α1,3gt).
|Transmission blocking vaccines for mosquito-borne flaviviruses|
Disclosed are transmission blocking vaccines for prevention or spread of one or more flaviviruses, and in particular, for prevention or spread of dengue virus. Vaccines can incorporate a polypeptide or a recombinant virus encoding a polypeptide that is non-homologous to human proteins and that is involved in flavivirus infection in a mosquito.
University Of South Carolina
|Recombinant mycobacterium bovis bcg expressing antigens of the mycobacterium marinum esx-1 secretion system|
recombinant strains of mycobacterium bovis bacille calmette-guerin (m. Bovis bcg) comprising a heterologous nucleic acid sequence of mycobacterium marinum (m.
|Biomarker directed multi-target immunotherapy|
This invention provides methods and compositions for using evaluating biomarker expression in a disease and providing a multi-targeted listeria-based immunotherapeutic approach against said disease. In a related aspect, the invention relates to a method of treating a disease in a subject, the method comprising the steps of: a.
|Multi-component-multistage malaria vaccines|
The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different plasmodium falciparum antigens from the pre-erythrocytic the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans.
Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.
|Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist of tim-3|
The invention relates to compositions, kits, and methods for cancer therapy using recombinant poxviruses encoding a tumor-associated antigen in combination with a monoclonal antibody against immune checkpoint molecule tim-3.. .
Bavarian Nordic A/s
Dystrophin gene exon deletion using engineered nucleases
The invention relates to the field of molecular biology and recombinant nucleic acid technology. In particular, the invention relates to methods of treating patients with duchenne muscular dystrophy comprising the removal of at least one exon from the dystrophin gene using engineered nucleases to restore the normal reading frame.
Precision Biosciences, Inc.
Use of long-acting human recombinant soluble tumor necrosis factor a receptor in the preparation of drugs for preventing and treating severe liver injury on chronic liver disease
The proposed invention involves the use of new drugs with the recombinant soluble tumor necrosis α receptor (hustnfr) and belongs to the gene engineering technology and gene function application field. This invention uses type i or type ii long-acting hustnfr (lhustnfr) to perform an intervention for severe liver injury in rats with chronic liver disease using 5 types of animal models.
Methods and compositions for expression of polypeptides in a cell
Disclosed herein are vector systems for expression of polypeptides in eukaryotic cells; and methods of obtaining high-level expression of polypeptides in a eukaryotic cell. Methods and compositions for obtaining stable, long-term expression of recombinant polypeptides are also provided.
Activity of fe-s cluster requiring proteins
The present invention is related to a recombinant host cell, in particular a yeast cell, comprising a dihydroxy-acid dehydratase polypeptide. The invention is also related to a recombinant host cell having increased specific activity of the dihydroxy-acid dehydratase polypeptide as a result of increased expression of the polypeptide, modulation of the fe—s cluster biosynthesis of the cell, or a combination thereof.
Butamax Advanced Biofuels Llc
Method of maintaining disease stability in a subject having gaucher's disease
A method of maintaining disease stability in a subject having gaucher's disease following switch from enzyme replacement therapy (ert) is provided. The method comprising orally administering to the subject a therapeutically effective amount of recombinant glucocerebrosidase (gcd) comprised in plant cells, thereby maintaining disease stability following switch..
Dna polymerases with improved activity
Disclosed are dna polymerases having increased reverse transcriptase efficiency relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods.
Roche Molecular Systems, Inc.
The present invention provides antibodies and antigen-binding fragments thereof that bind specifically to blys, immunoglobulin chains thereof, variants thereof; and method of use thereof, e.g., for the treatment or prevention of inflammatory and/or immune diseases such as systemic lupus erythramatous; as well as polynucleotides encoding the immunoglobulin chains of such antibodies and fragments. Methods for the recombinant expression of immunoglobulin chains are also part of the present invention..
Bispecific antibody fragments for neurological disease proteins and methods of use
The present invention relates to therapeutic agents comprising bispecific recombinant antibody fragments to selectively clear a protein associated with a neurological disease and methods of use of these therapeutic agents to treat neurological diseases.. .
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of
Ldlr variants and their use in compositions for reducing cholesterol levels
A recombinant vector having an expression cassette is provided which comprises a modified human low density lipoprotein receptor (hldlr) gene is provided, wherein said hldlr gene encodes a modified hldlr comprising (a) one or more of the following amino acid substitutions: l318h, n295d, h306d, v307d, n309a, d310n, l318h, and/or l318d; or (b) an amino acid substitution of any of (a) in combination with one or more of the following amino acid substitutions: k796, k809r and/or c818a. Also provided are pharmaceutical compositions containing this vector and uses therefor in lowering cholesterol and/or treating familial hypercholesterolemia..
The Trustees Of The University Of Pennsylvania
Methods and compositions comprising human recombinant growth and differentiation factor-5 (rhgdf-5)
Expression vector systems are provided for increased production of a recombinant gdf-5 (rhgdf-5) protein. Also provided are transformed host cells that were engineered to produce and express high levels of rhgdf-5 protein.
Warsaw Orthopedic, Inc.
Process for purification of darbepoetin alfa
The present invention provides sequential chromatography steps and conditions for purification of a recombinant protein, especially recombinant darbepoetin alfa.. .
Hetero Drugs Ltd.
Harvesting and perfusion apparatus
The present invention relates to an apparatus capable of harvesting a recombinant protein from a bioreactor having a porous container comprised of a chromatography medium capable of binding the recombinant protein and a method of use thereof.. .
Therapeutic Proteins International, Llc
Compositions and methods comprising klk3 or folh1 antigen
The present invention provides klk3 peptides, folh1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.. .
Means and methods for itaconic acid production
The present invention relates to a method of producing itaconic acid. Further the present invention relates to nucleic acids encoding an aconitate-delta-isomerase (adi) and trans-aconitate decarboxylase (tad) and uses of such nucleic acids.
Aav vectors for retinal and cns gene therapy
Provided herein are improved raav (e.g., raav2, raavrh8r, etc.) for enhanced gene therapy of ocular disorders or cns disorders wherein the raav comprise one or more substitutions of amino acids that interact with heparan sulfate proteoglycan. The invention provides methods for improved transduction of retinal cells and methods for treating ocular diseases with improved compositions of raav particles.
Enhanced expression and stability regions
Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (eesyrs) are provided for expression of a gene of interest in a eukaryotic cell.
Regeneron Pharmaceuticals, Inc.
Eukaryotic expression vectors resistant to transgene silencing
The present invention relates to recombinant dna molecules such as plasmids, non-viral vectors, viral vectors and hybrids thereof, and more particularly to vector modifications that improve expression of said dna molecules in cell lines and organisms.. .
Nature Technology Corporation
Polymerase compositions and kits, and methods of using and making the same
The present disclosure provides compositions, methods, kits, systems and apparatus that are useful for nucleic acid polymerization. In particular, recombinant polymerases and biologically active fragments thereof are provided that allow for nucleic acid amplification.
Life Technologies Corporation
Influenza m2 protein mutant viruses as live influenza attenuated vaccines
A method to prepare recombinant influenza viruses comprising a mutant m2 protein which has a deletion of two or more residues in the cytoplasmic tail and is attenuated in vivo, is provided, as well the resulting virus and vaccines with the virus.. .
Wisconsin Alumni Research Foundation (warf)
Soluble tumor necrosis factor receptor treatment of medical disorders
The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of tnfα by administering a tnfα antagonist, such as recombinant tnfr:fc.. .
Peptide tags for labeling proteins by fusion, and antibodies for the detection thereof
Peptide tags (tags) are provided for their fusion to proteins at the n-terminal or c-terminal ends, which are defined by a series of structural and functional properties that define their safety with regard to the modification of the structure or biological function of the protein or peptide to which they are fused, and wherein the tag-protein is selected from a group consisting of a fragment of phl p 2 pheleum pratense , a fragment of hev b 6.02 hevea brasiliensis, and a fragment of amb t 5 ambrosia trifida, or a combination thereof. Methods are also provided for the production and detection of these recombinant fusion proteins as well as specific antibodies that bind to these tags..
Instituto De BiologÍa Molecular De Barcelona- Consejo Superior De Investigaciones Cientificas
Anti-inflammatory compounds and methods of use
Disclosed herein are methods of treating or inhibiting inflammation in a subject by administering an anti-inflammatory protein to the subject. In some embodiments, the protein has at least 80% sequence identity to the amino acid sequence set forth as seq id no: 1 or fragments thereof.
University Of Oregon